Bulletin
Investor Alert

Market Pulse Archives

June 12, 2020, 8:46 a.m. EDT

FDA approves Viela's rare disease treatment, analysts predict $500 million in sales

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Viela Bio Inc. (VIE)
  • X
    Alexion Pharmaceuticals Inc. (ALXN)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Jaimy Lee

Shares of Viela Bio Inc. /zigman2/quotes/214411364/composite VIE -1.16% were up 4.9% in premarket trading on Friday, the day after the company received approval from the Food and Drug Administration (FDA) to market Uplizna to treat neuromyelitis optica spectrum disorder. It is the second treatment for the rare neuroinflammatory disorder to receive FDA approval. The drug helps reduce the risk of attacks that can lead to paralysis and blindness. Viela said it plans to launch Uplizna this month; a company spokesperson declined to provided pricing information at this time but said the drug will be priced "favorably" and "significantly lower" than Alexion Pharmaceuticals Inc.'s /zigman2/quotes/206262068/composite ALXN -0.36% Soliris. Stifel analysts predict roughly $500 million in sales of Uplizna in the U.S. per year. "From our review of the label, it looks largely in-line with base case expectations," they wrote in a June 12 note to investors. Viela's stock is up 89.5% year-to-date. The S&P 500 /zigman2/quotes/210599714/realtime SPX +0.30% is down 7.1% since the start of the year.

/zigman2/quotes/214411364/composite
US : U.S.: Nasdaq
$ 25.48
-0.30 -1.16%
Volume: 187,642
Sept. 24, 2020 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$1.41 billion
Rev. per Employee
N/A
loading...
/zigman2/quotes/206262068/composite
US : U.S.: Nasdaq
$ 112.02
-0.41 -0.36%
Volume: 1.25M
Sept. 24, 2020 4:00p
P/E Ratio
29.94
Dividend Yield
N/A
Market Cap
$24.64 billion
Rev. per Employee
$1.56M
loading...
/zigman2/quotes/210599714/realtime
US : S&P US
3,246.59
+9.67 +0.30%
Volume: 2.39B
Sept. 24, 2020 5:06p
loading...

This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »
Link to MarketWatch's Slice.